Senicapoc treatment in COVID‐19 patients with severe respiratory insufficiency—A randomized, open‐label, phase II trial

BACKGROUND: The aim of the current study was to determine if treatment with senicapoc, improves the PaO(2)/FiO(2) ratio in patients with COVID‐19 and severe respiratory insufficiency. METHODS: Investigator‐initiated, randomized, open‐label, phase II trial in four intensive care units (ICU) in Denmar...

Descripción completa

Detalles Bibliográficos
Autores principales: Granfeldt, Asger, Andersen, Lars W., Vallentin, Mikael F., Hilberg, Ole, Hasselstrøm, Jørgen B., Sørensen, Lambert K., Mogensen, Susie, Christensen, Steffen, Grejs, Anders M., Rasmussen, Bodil S., Kristiansen, Klaus T., Strøm, Thomas, Johansen, Isik S., Schjørring, Olav L., Simonsen, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Intensive Care and Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111301/
https://www.ncbi.nlm.nih.gov/pubmed/35403225
http://dx.doi.org/10.1111/aas.14072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111301/
https://www.ncbi.nlm.nih.gov/pubmed/35403225
http://dx.doi.org/10.1111/aas.14072

Ejemplares similares